Hematopoietic Stem Cell Transplantation (HSCT) activity was evaluated in the African (AFR)/EMRO region and compared to the global activity for the years 2006-2013. Data were obtained from 1570 teams in the 6 WHO continental regions. Of these, 29 (1.85%) of all teams were active in 12 of the 68 AFR/EMRO countries. They reported 2.331 (3.3%) of the worldwide 71.036 HSCT, and a transplant rate of 32.8 (TR; HSCT/10 million inhabitants; worldwide 128.5). This reflects still the lowest regional TR despite an increase of 90% since 2006. HSCT activity in AFR/EMRO countries was characterized by a higher use of allogeneic compared to autologous HSCT, an almost exclusive use of family donors, including haploidentical family donors. These findings contrast with the prevalence of autologous over allogeneic HSCT, and a higher frequency of unrelated HSCT in other parts of the world. Of note, the increase by 200% in HSCT for hemoglobinopathies from 2006 to 2013 (72 per year) in the AFR/EMRO region. This reflects the specific role of HSCT for these disease categories with high prevalence and incidence in the AFR/EMRO region. This report provides information for the competent authorities to foster adequate infrastructure. It urges transplant organization to optimize their cooperation.
Introduction
Hematopoietic stem cell transplantation (HSCT) has evolved from the beginnings of experimental bone marrow transplantation 60 years ago to a globally accepted successful therapy [1] . Transplantation of hematopoietic stem cells and tissues has extended the lifespan and enhanced the quality of life of hundreds of thousands of patients worldwide. Over the last two decades, global HSCT has seen a constant evolution in technology, a decrease in transplant-related mortality and rapid expansion. HSCT is no longer limited to younger patients or to patients with a matched donor. Novel conditioning regimens with lower intensity and new techniques have expanded the use of HSCT to older patients, to patients with comorbidities and to patients with haploidentical donors [1, 2] . Today, HSCT is an established but still complex form of therapy for patients with chemo-and immune-sensitive diseases, for the replacement of deficient cells or cellular components List of participating centers are given below Acknowledgments section.
and other life-threatening disorders. Its use has also been extended to severe inherited or acquired disorders of the hematopoietic system. However, HSCT is still associated with significant morbidity and mortality and remains an example of highcost and highly specialized medicine. It requires extensive experience, significant infrastructure and a network of specialists from all fields of medicine. It also requires the ability to provide specialist continued follow-up and management of patients. The accumulated experience covering a range of past errors and successes should therefore be used to improve access for all patients in need and serve as a model for the application of medical products of human origin in general.
Information on indications, the use of specific technologies, and trends in HSCT is essential for correct patient counseling and to allow health care agencies to prepare the necessary infrastructure and to avoid errors in planning. In addition, the guiding principles of the World Health Organization (WHO; www.who.org) declare the transplantation of organs, cells and tissues to be a global task, with the collection of activity data being one of the prime prerequisites [3] . The Worldwide Network for Blood and Marrow Transplantation (WBMT; www.wbmt.org), as an umbrella organization in the field of HSCT and a nongovernmental organization in working relation with the WHO, has taken up the challenge of collecting and disseminating worldwide HSCT data on a regular basis. The first report was based on the global HSCT activity in 2006 [4] , and was followed by a report on the data available in 2010 and thereafter a retrospective view of the first one million HSCTs in the year 2015 [5, 6] . The fourth report was focused on the HSCT activity in 2012 and looked at major trends since 2006 [7] . The report included a SWOT analysis of the current WBMT policy by key personnel in the field, to identify the strengths, weaknesses, opportunities, and threats of the current perspectives in HSCT.
In the current study, we analyzed the global HSCT activities reported between 2006 and 2013 concentrating on the African (AFR)/EMRO region in the global context regarding frequency, indication, donor type, and geographical distribution in 2013.
Patients and methods

Study design
This was a retrospective survey involving all HSCT teams known to the investigators, organized by WBMT through established international and/or regional organizations. No individual patient data were used, thus no ethics committee approval was mandated.
Participating groups, continents, countries, and teams Collection system and data validation were obtained as previously described [7] . Data were validated by different independent systems; through confirmation by the reporting teams, following receipt of a computer printout of the entered data, by selective comparison with MED-A/TED datasets in the EBMT or CIBMTR data system or by crosschecking with national registries. On-site visits to selected teams were part of the quality-control program within CIBMTR and EBMT teams. Based on quality controls and contacts with regulatory agencies or national offices, the response rate for allogeneic HSCT was estimated to be >95% and for autologous HSCT 80-90%. The survey focuses on the numbers of patients treated for the first time with HSCT. Transplant rates (TRs) were computed as the number of HSCT per 10 million inhabitants not corrected for population age. Population data were obtained from the US census office (http://www.census.gov).
Results
Transplant activities in the AFR/EMRO region from 2006 to 2013
Up to 34 centers from the AFR/EMRO region were noted to have HSCT activity during the period from 2006 to 2013 n.a.
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with fluctuations reflecting challenges in some centers that resulted in inconsistent activity over the years (Table 1 and  Figs. 1 and 2 ). In 2013, a total of 29 teams from 12 countries in the AFR/EMRO region provided activity data on a total of 2331 patients. The TR in active countries ranged from 0.1 to 109 for allogeneic HSCT compared to 0-173 for autologous HSCT. Several countries had no HSCT activity (Fig. 1) . Allogeneic TR ranged between 0 and 44 with the exception of Oman, Saudi Arabia, Jordan, and Lebanon (69.8, 96.1, 101.1, and 108.8 TR, respectively). For autologous HSCT, the TR ranged between 0 and 37 with the exception of Tunisia, Jordan, and Lebanon (52.6, 61.0, and 172.8 TR, respectively). These figures reflect the limited availability of transplant teams and limited logistic support in many countries of the region. In contrast to other world regions, more allogeneic (58%) than autologous (42%) HSCT were noted in the region (Fig. 2) . The AFR/EMRO region showed overall 90% increase in HSCT activity from 2006 to 2013 (1,230 to 2,331 transplants per year, respectively) with 69% increase in allogeneic HSCT and 129% increase in autologous HSCT (Table 1 ). Furthermore, 93% of patients undergoing allogeneic HSCT had a family donor and received peripheral blood stem cells (PBSC, 62%) or bone marrow (BM, 30%) as stem cell source. Cord blood (CB) transplants were in the range of 4% of all allogeneic HSCT. Major increases in allogeneic HSCT were seen for hemoglobinopathies (200%), lymphoproliferative diseases (114%), nonmalignant disorders in general (105%), and acute leukemias (89%; Table 1 ). Autologous HSCT was performed almost exclusively with PBSC and increased from 2006 in the African/EMRO region more than it did worldwide for patients with solid tumors (248% vs 9% respectively), plasma cell disorders (218% vs 76%, respectively), and lymphomas (107% vs 34%, respectively). As in the global survey, decreases were observed only in the use of autologous HSCT for leukemia (−41%). Interestingly, the HSCT per center/year was higher in Africa/EMRO than global (80 vs 45 HSCT/center/year, respectively; see Fig. 2 ). In comparison to the global survey, differences were noted in indications and donor types. The most striking differences include a more frequent use of allogeneic HSCT for bone marrow failure (17.9% of all allogeneic HSCT in Africa/EMRO as compared to 6.2% globally) and in autologous HSCT for lymphomas (44.6% of all autologous HSCT in Africa/EMRO as compared to 39.2% globally) and almost exclusive use of family donors in allogeneic HSCT. Centers in the AFR/EMRO region more frequently used haploidentical donors rather than cord blood to perform alternative donor HSCT (Fig. 3) . The proportion of HSCT using haploidentical donors as graft source started rising from 2009 (n = 41) to 2010 (n = 60), fell marginally in 2011, yet increased again in 2012 to peak in 2013 
Global HSCT activity, main indications, and donor type in 2013
The global HSCT activity in 2013 reached a new high of 71,036 transplants ( Table 1) . Most of the HSCT in 2013 were performed in Europe, followed by AMR/PAH, SEA/ WPR, and AFR/EMRO (47%, 30%, 20%, and 3%, respectively) with a steady and constant increase in activity in all 4 WHO regions. There was a slightly higher frequency of autologous (52.7%) compared to allogeneic (47.3%) HSCT. The main indications were lymphoproliferative disorders (n = 38,029; 53%) of which 88% (n = 33,447) were autologous and 12% (n = 4,582) allogeneic HSCT; leukemias (n = 25,246; 35%) of which 96% (n = 24,336) were allogeneic and 4% (n = 910) autologous HSCT; solid tumors (n = 2,909; 4%) of which 4% (n = 130) were allogeneic and 96% (n = 2779) autologous HSCT; non-malignant disorders (n = 4670; 7%) of which 94% (n = 4,380) were allogeneic and 6% (n = 290) autologous HSCT. The annual HSCT activity increased from 2006 to 2013 by 52.6% (Table 1) , while the number of reporting centers increased by 17.3% and plateaued in the years 2012-2013 (Fig. 2) . More importantly, HSCT per center increased from 35.1 to 45.2, confirming increased activity per center (Fig. 2) . Activity increased primarily for allogeneic HSCT (+65% from 2006) and, among these, especially for nonmalignant disorders (+86%), acute leukemias, MDS/MPS (+80%), and lymphoproliferative disorders (+42%; Table 1 ). Of all allogeneic HSCT, 51.4% were performed using an unrelated donor. Frequencies of autologous HSCT increased (+43%) most markedly in the PCD (+76%), nonmalignant disorders (+50%), and lymphoma (+34%) subgroups. Decreased activity was reported only in the use of autologous HSCT for leukemias (−47%).
Special attention was given to hemoglobinopathies as indication for HSCT in the AFR/EMRO region and worldwide. A total of 1033 HSCT were performed for these Two major changes were observed during the period 2006-2013. Firstly, HSCT from unrelated donors became more frequent than from related donors (Fig. 3) . Secondly, mismatched family or "haploidentical" donors increased from 1,186 (6% of allogeneic HSCT) in 2006 to 3,.830 (11.8% of allogeneic HSCT) in 2013. Worldwide, the use of haploidentical transplants became more common than that of unrelated cord blood in 2012 (Fig. 3 ).
Discussion
The current analysis is based on information on >464,100 HSCT reported to the WBMT over an 8-year period and explores distribution, donor choices, and HSCT techniques over time in the AFR/EMRO region and worldwide. The results allow several important conclusions.
Firstly, HSCT activity has been steadily increasing since 2006 in all world regions (even in high-HSCT performance regions) but to different degrees. For the first time, the number of HSCT per year exceeded 70,000, while there continue to be significant differences in TRs between the world regions. The relative increase was more prominent in countries with restricted resources, including AFR/EMRO, than in those with a high TR, but the TR still remains the lowest rate worldwide. Many countries, especially in central Africa do not have an active HSCT program.
Second, there is no indication of a plateau in activity. This continuing lack of saturation indicates underuse and implies that more patients would have been treated by HSCT had they had access and had donors been available. Obviously, this is more notable for hemoglobinopathies, which are highly prevalent in AFR/EMRO regions.
Third, the activity increase worldwide is mainly caused by augmented team activity with the median number of HSCT per team increasing from 29 to 41 between 2006 and 2013. Interestingly, the existing centers in the AFR/EMRO region have a median transplant activity higher than the corresponding global level, indicating the need for more HSCT centers. However, there was no increase in HSCT/ center in the analyzed region after 2007. This is probably a reflection of the low density of centers and a possible saturation for the center activity. The increase is only in part The proportion of uncaptured data, estimated to be <5% for allogeneic and <15% for autologous HSCT, also varied between the regions and was estimated to be lowest in the regions with the highest absolute numbers. Despite these limitations, it is unlikely that missing data would alter the overall interpretation. Significant changes were observed during the study period regarding donor type and graft source. Overall, unrelated HSCT exceeded related donor HSCT worldwide, particularly in Europe [8] , while related HSCT remained the almost exclusive graft source in the AFR/EMRO region [9, 10, 11] . Also, the incidence of haploidentical-related HSCT was consistently higher than CB HSCT in the AFR/EMRO region, while globally this was observed only in 2012. From 2012 onwards, worldwide interest in the use of unrelated CB seems to have started decreasing, while use of haploidentical donors is consistently increasing over this period with a steep rise after 2012. This may reflect a learning curve with some teams reducing the use of CB in favor of adopting the newer haploidentical transplant strategies. With fine tuning of haploidentical transplant techniques, this may have been perceived as a more cost-effective and logistically simpler strategy by some teams in this region. Double CB transplant, commonly used for adults, is associated with extra cost. This may also be a reflection of lack of unrelated donor registries and public CB banks in most of the AFR/EMRO region. Interestingly, the prominent use of allogeneic HSCT in comparison to autologous HSCT is a characteristic of the AFR/EMRO region.
Overall, only 1,033 HSCT were performed worldwide for hemoglobinopathies, of which only 216 were in the AFR/EMRO region. Considering the high prevalence and incidence of thalassemia (40,000 born annually and 80 million carriers; Modell, WHO Bulletin 2008) and of sickle cell anemia (e.g., 91,011 in Nigeria and 39,743 in Congo) in the AFR/EMRO region, this is clearly still lagging behind demand despite the recent increase [12] .
Ten years after its formation, WBMT has established itself as a global umbrella organization for HSCT. It has accomplished one of the prime prerequisites of WHO guiding principles on cell, organ, and tissue transplants: to collect, analyze, and disseminate information on global transplantation activity [3] . More than 1500 teams from 78 countries over all 6 continents contributed to the survey. Lack of a regional organization in some regions remains a clear limitation to the global survey and is an area in which support and expertise from the societies of the WBMT has helped since the establishment of the organization. In fact, two major societies were founded with the help of the WBMT: the LABMT and the AfBMT. While the LABMT has already published their first survey [13] , the AFR/ EMRO region is publishing its first report. Still many countries are without HSCT activities and this publication may aid in the development of further activity in the region. Initiatives of WBMT involve not only registries, but also regional WBMT workshops such as the most recent workshop organized at King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia in January 2017, under the auspices of the WHO. Telemedicine approaches have been tested for their efficacy in supporting program initiation and are now ready to be used on a larger scale. The WBMT has also been involved in counseling African countries planning to start an HSCT program.
The special position the WBMT has come to occupy as coordinator of global information in HSCT, has created a unique opportunity to build up a truly comprehensive worldwide network of standardized and quality controlled data collection and analysis. Further activities aim to collect outcome data on a global level, representing a major step toward the realization of the WHO principle that "data collection and data analysis remain integral parts of the therapy." WBMT will continue to interact with competent regulatory authorities to pursue the goal that costs and reimbursement for HSCT should include a component for comprehensive data and quality management. Obviously, in the AFR/EMRO region, there is a need for more HSCT centers in addition to progressive growth of existing centers.
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